Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1126]

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC...

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Pembrolizumab shows improvement in overall survival for clear cell renal cell...

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist show similar...

Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona...

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist show similar efficacy in high risk locally advanced PC ( Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

Study shows association between tumour KIM-1 gene (HAVCR1) expression and...

Dr Panagiotis Vlachostergios - IASO Thessalias General Hospital, Larissa, Greece

Study shows association between tumour KIM-1 gene (HAVCR1) expression and immune infiltrates in RCC ( Dr Panagiotis Vlachostergios - IASO Thessalias General Hospital, Larissa, Greece )

Guiding metastasis-directed therapy with different PET/CT radiotracers affects...

Dr Francesco Lanfranchi - University of Genoa, Genoa, Italy

Guiding metastasis-directed therapy with different PET/CT radiotracers affects distant disease control in HSPC patients ( Dr Francesco Lanfranchi - University of Genoa, Genoa, Italy )

Outcomes of radium-223 and SABR versus SABR for oligometastatic prostate cancers

Dr Ana Kiess - Johns Hopkins University, Baltimore, USA

Outcomes of radium-223 and SABR versus SABR for oligometastatic prostate cancers ( Dr Ana Kiess - Johns Hopkins University, Baltimore, USA )

Bladder cancer updates from the second half of 2024

Prof Alison Birtle, Dr Ignacio Durán and Dr Félix Guerrero-Ramos

Bladder cancer updates from the second half of 2024 ( Prof Alison Birtle, Dr Ignacio Durán and Dr Félix Guerrero-Ramos )

EMUC 2024: Optimising strategies in mHSPC and mCRPC

Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz

EMUC 2024: Optimising strategies in mHSPC and mCRPC ( Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz )

Precision oncology: Optimising therapeutic strategies in mHSPC and mCRPC

Prof. Gert Attard, Prof. Dr. Dr. Philipp Mandel, Dr. Lynda Corrigan

Precision oncology: Optimising therapeutic strategies in mHSPC and mCRPC ( Prof. Gert Attard, Prof. Dr. Dr. Philipp Mandel, Dr. Lynda Corrigan )

Debate: Challenges and solutions for new treatment options in mUC

Dr. María José Juan Fita, Dr. Bernadett Szabados, Prof. Rafael S. Grajewski, Dr...

Debate: Challenges and solutions for new treatment options in mUC ( Dr. María José Juan Fita, Dr. Bernadett Szabados, Prof. Rafael S. Grajewski, Dr. Diego Teyssonneau )

Fracture risk increases following cancer therapies for advanced prostate cancer

Dr Grace Lu-Yao - Thomas Jefferson University, Philadelphia, USA

Fracture risk increases following cancer therapies for advanced prostate cancer ( Dr Grace Lu-Yao - Thomas Jefferson University, Philadelphia, USA )

Expectations and priorities of older patients with cancer: the PRIORITY...

Dr Camille Chakiba - Institute Bergonié, Bordeaux, France

Expectations and priorities of older patients with cancer: the PRIORITY multicenter cohort study ( Dr Camille Chakiba - Institute Bergonié, Bordeaux, France )

More from ecancer